发布求助
文献互助 智能选刊 最新文献

Therapeutic delivery最新文献

筛选
英文 中文
Advantages and drawbacks of eco-friendly nano-delivery systems.
IF 3
Therapeutic delivery Pub Date : 2025-03-11 DOI: 10.1080/20415990.2025.2477441
Constantin Cerbu, Emilia Trif
{"title":"Advantages and drawbacks of eco-friendly nano-delivery systems.","authors":"Constantin Cerbu, Emilia Trif","doi":"10.1080/20415990.2025.2477441","DOIUrl":"https://doi.org/10.1080/20415990.2025.2477441","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-3"},"PeriodicalIF":3.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of chloramphenicol derivative N-phenyl 2, 2 dichloroacetamide anticancer and antibacterial properties.
IF 3
Therapeutic delivery Pub Date : 2025-03-10 DOI: 10.1080/20415990.2025.2476928
Arwa Al Khatib, Anas Abed, Hamdi Nsairat, Mohamed El-Tanani, Muhammad Yaqoob, Hisham Al-Obaidi
{"title":"Evaluation of chloramphenicol derivative N-phenyl 2, 2 dichloroacetamide anticancer and antibacterial properties.","authors":"Arwa Al Khatib, Anas Abed, Hamdi Nsairat, Mohamed El-Tanani, Muhammad Yaqoob, Hisham Al-Obaidi","doi":"10.1080/20415990.2025.2476928","DOIUrl":"https://doi.org/10.1080/20415990.2025.2476928","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to develop microparticles of N-phenyl-2,2-dichloroacetamide (PDA), a chloramphenicol derivative with potential antibacterial and anticancer properties, to improve drug release and selectivity while reducing toxicity.</p><p><strong>Materials & methods: </strong>PDA microparticles were prepared via spray-drying using L-leucine, Trehalose, and Mannitol. The particles were characterized for size, drug release, antibacterial activity, and cytotoxicity against A549 cancer cells and fibroblasts.</p><p><strong>Results: </strong>PDA formulations exhibited controlled release and enhanced selectivity for cancer cells. S1 showed antibacterial activity against S. aureus. L-leucine formulations had reduced toxicity to normal fibroblasts.</p><p><strong>Conclusions: </strong>PDA microparticles offer potential as safer, targeted antibacterial and anticancer therapies, providing controlled release and reduced side effects.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced delivery systems for oxygen therapeutics: center around red blood cells.
IF 3
Therapeutic delivery Pub Date : 2025-03-09 DOI: 10.1080/20415990.2025.2475737
Wujie Zhang, Michael Navin
{"title":"Advanced delivery systems for oxygen therapeutics: center around red blood cells.","authors":"Wujie Zhang, Michael Navin","doi":"10.1080/20415990.2025.2475737","DOIUrl":"https://doi.org/10.1080/20415990.2025.2475737","url":null,"abstract":"<p><p>Oxygen therapeutics hold great potential as alternatives to red blood cell/whole blood transfusions. The development of hemoglobin-based oxygen carriers began in the 1930s, but, regrettably, none have received FDA approval. This review starts with an overview of red blood cell physiology and then focuses on hemoglobin-based oxygen therapeutics (including modified and encapsulated hemoglobin) as well as red blood cell mimetics, particularly regarding their size and shape. The review also addresses the different approaches to hemoglobin-based oxygen carriers.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry update: the latest developments in the field of therapeutic delivery, December 2024.
IF 3
Therapeutic delivery Pub Date : 2025-03-06 DOI: 10.1080/20415990.2025.2472722
Peter Timmins
{"title":"Industry update: the latest developments in the field of therapeutic delivery, December 2024.","authors":"Peter Timmins","doi":"10.1080/20415990.2025.2472722","DOIUrl":"https://doi.org/10.1080/20415990.2025.2472722","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
November Industry News.
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI: 10.1080/20415990.2025.2469483
Fiona McCartney
{"title":"November Industry News.","authors":"Fiona McCartney","doi":"10.1080/20415990.2025.2469483","DOIUrl":"10.1080/20415990.2025.2469483","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"199-204"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced drug delivery systems for the management of local conditions.
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2024-12-29 DOI: 10.1080/20415990.2024.2437978
Lucía Lopez-Vidal, Kornelija Juskaite, Inken K Ramöller, Daniel A Real, Peter E McKenna, Josefina Priotti, Ryan F Donnelly, Alejandro J Paredes
{"title":"Advanced drug delivery systems for the management of local conditions.","authors":"Lucía Lopez-Vidal, Kornelija Juskaite, Inken K Ramöller, Daniel A Real, Peter E McKenna, Josefina Priotti, Ryan F Donnelly, Alejandro J Paredes","doi":"10.1080/20415990.2024.2437978","DOIUrl":"10.1080/20415990.2024.2437978","url":null,"abstract":"<p><p>Localized disorders, even though originally confined to a specific body part, can progress into potentially life-threatening systemic disorders if treated inappropriately. Local treatment is often highly challenging due to poor penetration of therapeutic agents from their vehicles into the affected body site. Systemic treatment on the other hand often comes with unspecific side effects. The skin is the largest organ of the body, and conditions such as wounds and bacterial or fungal infections disrupt its natural barrier properties, important for the homeostasis of the human body. Advanced drug delivery systems for treating these conditions could greatly improve the treatment outcome and patient compliance. Other parts of the body that are of interest regarding localized treatment are, for example, the eyes along with mucosal tissues which are present in the vagina and lungs. Rather than focusing on specific diseases or parts of the body, this review provides an overview of the different drug delivery platforms that have been employed for enhanced local treatment. The following systems will be discussed: nanoparticle-based systems, such as nanocrystals, polymeric, lipidic, and inorganic nanoparticles, and nanogels; cyclodextrin inclusion complexes; and several devices like microarray patches, wound dressings, and films.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"16 3","pages":"285-303"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastroretentive microballoons of olmesartan medoxomil: formulation and in vitro-in vivo evaluation.
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2025-02-25 DOI: 10.1080/20415990.2025.2466418
Archana S Patil, Shweta Aloshi, Yadishma Gaude, Rajashree S Masareddy
{"title":"Gastroretentive microballoons of olmesartan medoxomil: formulation and <i>in vitro-in vivo</i> evaluation.","authors":"Archana S Patil, Shweta Aloshi, Yadishma Gaude, Rajashree S Masareddy","doi":"10.1080/20415990.2025.2466418","DOIUrl":"10.1080/20415990.2025.2466418","url":null,"abstract":"<p><strong>Background: </strong>Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%.</p><p><strong>Materials and methods: </strong>Microballoons of Olmesartan medoxomil were formulated using the ionotropic gelation technique and subjected to various evaluation parameters.</p><p><strong>Results: </strong>The particles were found to be in the range of 85.11 to 312.6 µm. The prepared microballoons remained buSSoyant for more than 12 hours and showed percentage of cumulative drug release between 56.32-83.62%. <i>In vivo</i> studies showed significant reduction in Systolic blood pressure (SBP) in optimized formulation (OF).</p><p><strong>Conclusion: </strong>The formulated microballoons (hollow microspheres) emerged as a promising option for an oral gastro retentive controlled drug delivery system for Olmesartan medoxomil.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"227-236"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143504251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens. 抗击临床相关病原体的噬菌体治疗传递方法和临床试验。
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2024-11-15 DOI: 10.1080/20415990.2024.2426824
Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab
{"title":"Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.","authors":"Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab","doi":"10.1080/20415990.2024.2426824","DOIUrl":"10.1080/20415990.2024.2426824","url":null,"abstract":"<p><p>The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various <i>in vitro</i> and <i>in vivo</i> studies denoted their eminent bactericidal and anti-biofilm potential. This review addresses the latest developments in phage therapy regarding their attack strategies, formulations, and administration routes. It additionally discusses and elaborates on the status of phage therapy undergoing clinical trials, and the challenges encountered in their usage, and explores prospects in phage therapy research and application.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"247-269"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SN-38-indoximod conjugate: carrier free nano-prodrug for cancer therapy.
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2025-01-31 DOI: 10.1080/20415990.2025.2458449
Sanjay Kumar, Yoshitaka Koseki, Keita Tanita, Aki Shibata, Asuka Mizutani, Hitoshi Kasai
{"title":"SN-38-indoximod conjugate: carrier free nano-prodrug for cancer therapy.","authors":"Sanjay Kumar, Yoshitaka Koseki, Keita Tanita, Aki Shibata, Asuka Mizutani, Hitoshi Kasai","doi":"10.1080/20415990.2025.2458449","DOIUrl":"10.1080/20415990.2025.2458449","url":null,"abstract":"<p><strong>Background: </strong>The integration of immunotherapy alongside chemotherapy represents a crucial approach in the treatment of cancer. Herein we report the SN-38-indoximod conjugate nano-prodrug to address the difficulties encountered by individuals. In this prodrug, SN-38 is connected to indoximod through a specific disulfide linker, which enables the release of the components in response to the tumor microenvironment characterized by elevated levels of glutathione, thereby facilitating programmed chemoimmunotherapy.</p><p><strong>Results: </strong>SN-38-indoximod conjugate was synthesized and fabricated to nano-prodrug by reprecipitation method. It showed comparable anti-cancer activity against A549 cells than SN-38 (IC<sub>50</sub> = 0.24 ± 0.01 µM) with IC<sub>50</sub> value 0.32 ± 0.04 µM. It inhibited 90% A549 cell at very lower concentration (IC<sub>90</sub> = 6.07 ± 0.41 µM) as compared with SN-38 (IC<sub>90</sub> = 24.60 ± 1.24 µM) and mixture of SN-38: indoximod (1:1, IC<sub>90</sub> >30 µM). The nano-prodrug showed better size distribution profile and dispersion stability contains nanoparticles in effective size range (80-160 nm) required for the EPR effect.</p><p><strong>Conclusion: </strong>This research offers valuable insights into the advancement of conjugate nano-prodrugs exhibiting synergistic pharmacological effects, while also presenting novel opportunities for the design of prodrug molecules capable of releasing drugs in response to diverse triggers.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"217-226"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system. 自纳米乳化厄洛替尼给药系统的生物利用度和抗胰腺癌疗效研究
IF 3
Therapeutic delivery Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI: 10.1080/20415990.2025.2466412
Maryam Karimi, Rezvan Dehdari Vais, Khashayar Karimian, Alireza Parsaei, Hossein Heli
{"title":"Investigation of bioavailability and anti-pancreatic cancer efficacy of a self-nanoemulsifying erlotinib delivery system.","authors":"Maryam Karimi, Rezvan Dehdari Vais, Khashayar Karimian, Alireza Parsaei, Hossein Heli","doi":"10.1080/20415990.2025.2466412","DOIUrl":"10.1080/20415990.2025.2466412","url":null,"abstract":"<p><strong>Aims: </strong>A new self-nanoemulsifying drug delivery system (SNEDDS) was developed for erlotinib (Ert) oral delivery.</p><p><strong>Materials and methods: </strong>A pseudo-ternary phase diagram for olive oil, Tween 80 and polyethylene glycol (PEG) 600 mixtures, was firstly constructed. Based on the data about Ert solubility and cytotoxicity of these components, a SNEDDS composed of 10% olive oil, 20% Tween 80 and 70% (V/V) polyethylene glycol 600 was selected for Ert loading (Ert-SNEDDS).</p><p><strong>Results and conclusions: </strong>SNEDDS formed 31.2-nm droplets upon dilution in water, and Ert loading led to increment in the oil droplets to 83.9 ± 0.6 nm. Ert-SNEDDS represented a loading capacity and an entrapment efficiency of 22.7 ± 0.7 and 40.7 ± 0.5%, respectively. Ert release from Ert-SNEDDS was monitored in both a mixture of phosphate buffer saline and 0.5% Tween 80, and artificial gastric fluid. Ert-SNEDDS was orally administrated in rats, and the Ert plasma level was monitored over time to measure pharmacokinetic parameters. Ert-SNEDDS led to enhancement in the drug bioavailability and changed the release route of Ert. Ert-SNEDDS showed enhanced cytotoxicity toward ASPC-1 and PANC-1 cells, and half-maximal inhibitory concentration values were obtained and compared with free Ert. Ert-SNEDDS may be considered as an alternative route for oral Ert delivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"237-246"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信